Effect of ACE inhibition on the fibrinolytic system in patients requiring coronary artery bypass grafting

Thoracic and Cardiovascular Surgeon

Volumn 57, Issue 6, 2009, Pages 368-369

  Walter, T ^a   Szabo, S ^b   Kazmaier, S ^b   Suselbeck, T ^a   Borggrefe, M ^a   Hoffmeister, H M ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Staedtisches Klinikum   (Germany)

Author keywords

ACE inhibitor; Coronary bypass surgery; Plasmin alpha2 antiplasmin complex; Plasminogen activator inhibitor; Tissue type plasminogen activator

Indexed keywords

ALPHA 2 ANTIPLASMIN; D DIMER; ENALAPRIL; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ALLERGIC REACTION; ANGINA PECTORIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FEMALE; FIBRINOLYSIS; HUMAN; HYPOTENSION; MALE; OPERATION DURATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; TREATMENT DURATION;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIPLASMIN; BIOLOGICAL MARKERS; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DOUBLE-BLIND METHOD; ENALAPRIL; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; HUMANS; MALE; MIDDLE AGED; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSPECTIVE STUDIES; RENIN-ANGIOTENSIN SYSTEM; SEVERITY OF ILLNESS INDEX; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 70350492902     PISSN: 01716425     EISSN: 14391902     Source Type: Journal    
DOI: 10.1055/s-0029-1185596     Document Type: Article

References (18)

1. Kerlns DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 1995; 96 (5): 2515-2520
2. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995; 95: 995-1001
3. Huber K, Christ G, Wojta J, Gulba D. Plasminogen activator inhibitor type-1 in cardiovascular disease. Status report 2001. Thromb Res 2001; 103 (Suppl. 1): S7-S19 (Pubitemid 32913248)
4. Brown NJ, Nadeau JH, Vaughan DE. Selective Stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thromb Haemost 1997; 77 (3); 522-555
5. Francis Jr RB, Kawanishi D, Baruch T, Mahrer P, Rahimtoola S, Feinstein Di. Impaired fibrinolysis in coronary artery disease. Am Heart J1988; 115:776-780
6. Hoffmeister HM, Jur M, Wendel HP, Heller W, Seipel L. Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris. Circulation 1995; 91: 2520-2527
7. Pretorius M, Murphey LJ, McFarlane JA, Vaughan DE, Brown NJ. Angiotensin-Converting enzyme inhibition alters the fibrinolytic response to cardiopulmonary bypass. Circulation 2003; 108 (25): 3079-3083 (Pubitemid 38031795)
8. Walter T, Helber U, Bail D, Heller W, Hoffmeister HM. Influence of ACE inhibition on myocardial damage, the kallikrein-kinin system and hemostasis during cardiopulmonary bypass surgery. Thorac Cardiovasc Surg 2002; 50(3): 150-154 (Pubitemid 34760509)
9. Fogari R, Zoppi A. Is the effect of antihypertensive drugs on platelet aggregability and fibrinolysis clinically relevant? Am J Cardiovasc Drugs 2005; 5 (4): 211-223
10. Vaughan DE, Rouleau JL, Ridker PM, Arnold JM, Meapace FJ, Pfeffer MA. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. Circulation 1997; 96 (2): 442-447
11. Wright RA, Flapan AD, Alberti KGMM, Ludlam CA, Fox KAA. Effects of Captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol 1994; 24: 67-73
12. Brown NJ, Kumar S, Painter CA, Vaughan DE. ACE Inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time. Hypertension 2002; 40 (6): 859-865 (Pubitemid 35434907)
13. Tsikouris JP, Suarez JA, Meyerrose GE, Ziska M, Fike D, SmithJ. Questioning a class effect: does ACE inhibitor tissue penetration influence the degree of fibrinolytic balance alteration following an acute myocardial infarction? J Clin Pharmacol 2004; 44 (2): 150-157
14. Lottermosei- K, Wostmann B, Weissei- B et al. Effects of Captopril on fibrinolytic function in healthy humans. Eur J Med Res 1999; 4 (1): 31-34
15. Zehetgruber M, Beckmann R, Gabriel H, Christ G, Binder BR, Huber K. The ACE-inhlbitor lisinopril affects plasma insulin levels but not fibrinolytic parameters. Thromb Res 1996; 83: 143-152 (Pubitemid 26274432)
16. Pretorius M, Murphey LJ, McFarlane JA, Vaughan DE, Brown NJ. Angiotensin-Converting enzyme inhibition alters the fibrinolytic response to cardiopulmonary bypass. Circulation 2003; 108 (25): 3079-3083 (Pubitemid 38031795)
17. Remkova A, Kratochvilova H. Effect of the angiotensin-converting enzyme inhibitor Perindopril on haemostasis in essential hypertension. Blood Coagul Fibrinolysis 2000; 11 (7): 641-644 (Pubitemid 30819668)
18. Gram J. The haemostatic balance in groups of thrombosis-prone patients. With particular reference to fibrinolysis in patients with myocardial infarction. Dan Med Bull 1990; 37: 210-234